J&J and Protagonist’s UC pill goes to Phase III after mid-stage success
Analysts note icotrokinra could be a competitive player in the UC market if it were to be approved due to its oral administration.
08 October 2025
08 October 2025
Analysts note icotrokinra could be a competitive player in the UC market if it were to be approved due to its oral administration.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.